We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Nastech Presents In Vitro and In Vivo Results with its RNAi Therapeutics Program for Influenza

News   Mar 20, 2006

 
Nastech Presents In Vitro and In Vivo Results with its RNAi Therapeutics Program for Influenza
 
 
 

RELATED ARTICLES

Tracking Down Missing-in-Action Multiple Sclerosis Genes

News

Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.

READ MORE

Marker May Help Target Treatments for Crohn’s Patients

News

Accurately predicting which subtype of Crohn's disease is likely to develop has not been possible, until now.

READ MORE

The Making of Soldier Ants

News

Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE